Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Asian Pac J Cancer Prev ; 14(5): 2967-71, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23803063

RESUMEN

BACKGROUND: Extraskeletal Ewing sarcoma (EES)/primitive neuroectodermal tumours (PNET) are rare soft tissue sarcomas. Prognostic factors and optimal therapy are still unconfirmed. MATERIALS AND METHODS: We performed a retrospective analysis on patients to explore the clinic characteristics and prognostic factors of this rare disease. A total of 37 patients older than 15 years referred to our institute from Jan., 2002 to Jan., 2012 were reviewed. The characteristics, treatment and outcome were collected and analyzed. RESULTS: The median age was 28 years (range 15-65); the median size of primary tumours was 8.2 cm (range 2-19). Sixteen patients (43%) had metastatic disease at the initial presentation. Wide surgical margins were achieved in 14 cases (38%). Anthracycline or platinum-based chemotherapy was performed on 29 patients (74%). Radiotherapy was delivered in 13 (35%). At a median follow-up visit of 24 months (range 2-81), the media event-free survival (EFS) and overall survival (OS) were 15.8 and 30.2 months, respectively. The 3-year EFS and OS rates were 24% and 43%, respectively. Metastases at presentation and wide surgical margins were significantly associated with OS and EFS. Tumour size was significantly associated with OS but not EFS. There were no significant differences between anthracycline and platinum based chemotherapy regarding EFS and OS. CONCLUSIONS: EES/PNET is a malignant tumour with high recurrence and frequent distant metastasis. Multimodality therapy featuring wide surgical margins, aggressive chemotherapy and adjuvant local radiotherapy is necessary for this rare disease. Platinum-based chemotherapy can be used as an adjuvant therapy.


Asunto(s)
Antraciclinas/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Tumores Neuroectodérmicos/tratamiento farmacológico , Compuestos de Platino/uso terapéutico , Sarcoma de Ewing/tratamiento farmacológico , Adolescente , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/mortalidad , Neoplasias Óseas/radioterapia , Neoplasias Óseas/cirugía , Terapia Combinada , Supervivencia sin Enfermedad , Humanos , Persona de Mediana Edad , Metástasis de la Neoplasia/patología , Recurrencia Local de Neoplasia , Tumores Neuroectodérmicos/mortalidad , Tumores Neuroectodérmicos/radioterapia , Tumores Neuroectodérmicos/cirugía , Estudios Retrospectivos , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/radioterapia , Sarcoma de Ewing/cirugía , Tasa de Supervivencia , Adulto Joven
2.
Klin Padiatr ; 217(3): 153-7, 2005.
Artículo en Alemán | MEDLINE | ID: mdl-15858707

RESUMEN

Supratentorial primitive neuroectodermal tumors (stPNETs) are malignant tumors. We saw within three years six children with stPNETs. In four of the six children radical resection could be achieved. All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol. The two children with incomplete resection died due to tumor progression after 7 and 10 months. Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months. One child had a diffuse meningeal relapse 12 months after diagnosis. Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved. Only one child is still in remission 86 months after diagnosis.


Asunto(s)
Neoplasias Encefálicas , Núcleos Cerebelosos , Cuerpo Calloso , Lóbulo Frontal , Tumores Neuroectodérmicos , Lóbulo Occipital , Lóbulo Parietal , Lóbulo Temporal , Tálamo , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirugía , Neoplasias del Tronco Encefálico/secundario , Neoplasias Cerebelosas/mortalidad , Neoplasias Cerebelosas/cirugía , Niño , Preescolar , Terapia Combinada , Progresión de la Enfermedad , Humanos , Masculino , Mesencéfalo , Recurrencia Local de Neoplasia , Tumores Neuroectodérmicos/tratamiento farmacológico , Tumores Neuroectodérmicos/mortalidad , Tumores Neuroectodérmicos/radioterapia , Tumores Neuroectodérmicos/cirugía , Pronóstico , Inducción de Remisión , Factores de Tiempo
3.
J Neurooncol ; 40(1): 29-38, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9874183

RESUMEN

It is our hypothesis that low grade gliomas are the glial counterparts of other precancerous lesions such as colon polyps and, therefore, suitable targets for chemoprevention. Steps in the molecular progression of gliomas have been described, indicating that an accumulation of abnormalities is required for progression to a high grade and interruption of this progression might be possible. An animal model of chemical glial carcinogenesis was used to test this hypothesis. Pregnant rats were injected intravenously with ENU (ethylnitrosourea) on the 18th day of gestation to induce gliomas in the offspring, which were randomized to receive control diet, diet supplemented with vitamin A palmitate, or diet supplemented with N-acetylcysteine. Animals exposed to ENU and receiving a control diet developed brain tumors and had a shortened life expectancy compared with rats unexposed to ENU. The animals treated with NAC showed no statistically significant delay in the time to tumor and no change in the histologic grade of the tumors when compared with animals receiving control diet, but the time to death from any cause of NAC treated animals differed significantly from untreated animals. Animals receiving high dose VA had statistically significantly prolonged time to tumor, survived significantly longer than untreated animals, but had no reduction in the total number of tumors or change in the histologic grade of their tumors. The theoretical basis of these results is likely due to the putative mechanism of action of these agents. These data indicate that glioma chemoprevention is possible and deserves further exploration.


Asunto(s)
Acetilcisteína/farmacología , Neoplasias Encefálicas/tratamiento farmacológico , Depuradores de Radicales Libres/farmacología , Glioma/tratamiento farmacológico , Vitamina A/farmacología , Animales , Neoplasias Encefálicas/inducido químicamente , Neoplasias Encefálicas/mortalidad , Carcinógenos , Etilnitrosourea , Femenino , Glioma/inducido químicamente , Glioma/mortalidad , Tumores Neuroectodérmicos/inducido químicamente , Tumores Neuroectodérmicos/tratamiento farmacológico , Tumores Neuroectodérmicos/mortalidad , Embarazo , Ratas , Ratas Sprague-Dawley , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA